CAMBRIDGE, Mass.--(BUSINESS WIRE)--Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) announced today that it will present study results on four of its oncology candidates at the 55th annual meeting of the Society of Nuclear Medicine (SNM). The meeting will take place June 14 -18, 2008 in New Orleans, LA. Presentations will include data on Azedra™ (Ultratrace™ 131I-MIBG), the company’s targeted radiotherapeutic candidate for the treatment of neuroendocrine tumors; Trofex™, its molecular imaging radiopharmaceutical candidate for the detection and monitoring of prostate cancer; Onalta™, a targeted radiotherapeutic complementary to Azedra that is in development for the treatment of neuroendocrine tumors such as carcinoid; and Solazed™, a targeted radiotherapeutic in development for the treatment of metastatic melanoma. The abstract and presentation details are as follows:
